Polaris Partners

Polaris Partners is a multibillion-dollar investment firm founded in 1996 and headquartered in Boston, Massachusetts, with an additional office in San Francisco. The firm specializes in investing in healthcare and biotechnology companies, focusing on various aspects of the sector. Its healthcare portfolio includes companies that develop innovative care delivery models, such as digital health solutions, consumer-centric services, patient-provider interactions, as well as data science and analytics. In the biotechnology realm, Polaris targets life sciences firms engaged in research and development of therapeutics, genomic technologies, and molecular platforms. With over 20 years of experience, Polaris Partners collaborates with repeat entrepreneurs and innovators, supporting ventures from their inception through to profitable growth.

David Barrett

General Partner

Marissa Bertorelli

Principal

Alexandra Cantley

Partner

Darren Carroll

Partner

Brian Chee

Managing Partner

Harold Friedman

CFO

Dan Lombard

Partner

Eileen McGuire

Partner

Pat Mulach

Associate

Gary Swart

Partner

Sabrina Chiasson

Vice President

Past deals in Health Care

Vytyl Health Management

Venture Round in 2023
Vytyl Health Management delivers quality mental health care to adolescents and transitional-age youth. The organization firmly believes that connection forms the basis for healing. They recognize the significant challenges ahead but remain steadfast in their conviction that through collaborative efforts, barriers can be overcome, meaningful bonds can be formed, and vital assistance can be extended to those in greatest need.

Nomad Health

Venture Round in 2022
Nomad Health, Inc. operates an online marketplace that connects clinicians with freelance and permanent healthcare jobs across the United States. Founded in 2015 and headquartered in New York, the company provides a platform where doctors and nurses can search for job opportunities based on various criteria, including location, pay rate, and medical specialty. By digitizing the healthcare hiring process, Nomad Health simplifies and modernizes staffing in the healthcare sector, allowing healthcare facilities to efficiently find qualified clinicians. The platform also manages digital resumes and credentials, facilitating communication and organization between clinicians and health systems, while assisting with insurance, applications, travel arrangements, and payment processes.

Podimetrics

Series C in 2022
Podimetrics, Inc. is a care management company focused on preventing diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and headquartered in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless monitoring system that allows patients to scan their foot temperatures at home for just 20 seconds daily. This FDA-cleared device automatically transmits data to the company's clinical support team, which monitors for any concerning findings. By integrating advanced technology with effective care management, Podimetrics enhances patient engagement and enables clinicians to achieve improved health outcomes, ultimately saving limbs, lives, and healthcare costs. The company is supported by notable investors, including Norwich Ventures and Rock Health.

Nomad Health

Series D in 2021
Nomad Health, Inc. operates an online marketplace that connects clinicians with freelance and permanent healthcare jobs across the United States. Founded in 2015 and headquartered in New York, the company provides a platform where doctors and nurses can search for job opportunities based on various criteria, including location, pay rate, and medical specialty. By digitizing the healthcare hiring process, Nomad Health simplifies and modernizes staffing in the healthcare sector, allowing healthcare facilities to efficiently find qualified clinicians. The platform also manages digital resumes and credentials, facilitating communication and organization between clinicians and health systems, while assisting with insurance, applications, travel arrangements, and payment processes.

PathAI

Series C in 2021
PathAI, Inc. is a company that develops artificial intelligence-based technology solutions aimed at enhancing the accuracy and efficiency of pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI's platform utilizes machine and deep learning techniques to process large datasets, enabling pathologists to diagnose cancer and other conditions rapidly and accurately. The technology not only assists in making precise diagnoses but also identifies patients who may benefit from innovative therapies, thereby facilitating personalized medicine. PathAI addresses complex challenges in pathology for both the research and pharmaceutical industries, providing reliable and scalable solutions.

Podimetrics

Series B in 2020
Podimetrics, Inc. is a care management company focused on preventing diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and headquartered in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless monitoring system that allows patients to scan their foot temperatures at home for just 20 seconds daily. This FDA-cleared device automatically transmits data to the company's clinical support team, which monitors for any concerning findings. By integrating advanced technology with effective care management, Podimetrics enhances patient engagement and enables clinicians to achieve improved health outcomes, ultimately saving limbs, lives, and healthcare costs. The company is supported by notable investors, including Norwich Ventures and Rock Health.

Iora Health

Series F in 2020
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Podimetrics

Series B in 2019
Podimetrics, Inc. is a care management company focused on preventing diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and headquartered in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless monitoring system that allows patients to scan their foot temperatures at home for just 20 seconds daily. This FDA-cleared device automatically transmits data to the company's clinical support team, which monitors for any concerning findings. By integrating advanced technology with effective care management, Podimetrics enhances patient engagement and enables clinicians to achieve improved health outcomes, ultimately saving limbs, lives, and healthcare costs. The company is supported by notable investors, including Norwich Ventures and Rock Health.

Nomad Health

Series C in 2019
Nomad Health, Inc. operates an online marketplace that connects clinicians with freelance and permanent healthcare jobs across the United States. Founded in 2015 and headquartered in New York, the company provides a platform where doctors and nurses can search for job opportunities based on various criteria, including location, pay rate, and medical specialty. By digitizing the healthcare hiring process, Nomad Health simplifies and modernizes staffing in the healthcare sector, allowing healthcare facilities to efficiently find qualified clinicians. The platform also manages digital resumes and credentials, facilitating communication and organization between clinicians and health systems, while assisting with insurance, applications, travel arrangements, and payment processes.

Iora Health

Series E in 2018
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Nomad Health

Series B in 2018
Nomad Health, Inc. operates an online marketplace that connects clinicians with freelance and permanent healthcare jobs across the United States. Founded in 2015 and headquartered in New York, the company provides a platform where doctors and nurses can search for job opportunities based on various criteria, including location, pay rate, and medical specialty. By digitizing the healthcare hiring process, Nomad Health simplifies and modernizes staffing in the healthcare sector, allowing healthcare facilities to efficiently find qualified clinicians. The platform also manages digital resumes and credentials, facilitating communication and organization between clinicians and health systems, while assisting with insurance, applications, travel arrangements, and payment processes.

Quartet Health

Series C in 2018
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the platform integrates with health plans and systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. By facilitating connections among physicians, mental health providers, and insurers, Quartet Health enhances access to mental health care that aligns with patients' preferences and clinical needs, while also supporting tools for patient self-management. This approach not only improves the quality of care but also contributes to lowering healthcare costs for patients.

Compass Therapeutics

Series A in 2017
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for solid tumors and hematological malignancies. Founded in 2014 and based in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to identify and develop innovative antibody therapeutics. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase I clinical trials. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, and has completed a Phase 1 dose escalation study. Additionally, CTX-8371, another bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Compass Therapeutics aims to engage the immune system effectively to advance its therapeutic offerings.

Iora Health

Series D in 2016
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Quartet Health

Series B in 2016
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the platform integrates with health plans and systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. By facilitating connections among physicians, mental health providers, and insurers, Quartet Health enhances access to mental health care that aligns with patients' preferences and clinical needs, while also supporting tools for patient self-management. This approach not only improves the quality of care but also contributes to lowering healthcare costs for patients.

Pulmatrix

Post in 2015
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, specializing in the development of inhaled therapies for serious pulmonary diseases. Utilizing its proprietary iSPERSE technology, Pulmatrix focuses on creating innovative dry powder delivery systems to enhance therapeutic delivery to the lungs. The company's product pipeline includes Pulmazole, an inhaled anti-fungal treatment for patients with allergic bronchopulmonary aspergillosis, and PUR1800, a narrow-spectrum kinase inhibitor aimed at treating obstructive lung diseases such as asthma and chronic obstructive pulmonary disease. Pulmatrix has established partnerships with RespiVert Ltd. for the development of kinase inhibitors and with Cipla Technologies LLC to commercialize Pulmazole. Founded in 2003, Pulmatrix aims to address significant unmet medical needs in respiratory health through its advanced therapeutic solutions.

Quartet Health

Series A in 2015
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the platform integrates with health plans and systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. By facilitating connections among physicians, mental health providers, and insurers, Quartet Health enhances access to mental health care that aligns with patients' preferences and clinical needs, while also supporting tools for patient self-management. This approach not only improves the quality of care but also contributes to lowering healthcare costs for patients.

Iora Health

Series C in 2015
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

First Opinion

Series A in 2014
First Opinion is like having a doctor in the family and from the convenience of your phone or computer. Doctors are available within minutes, 24-hours a day for all of your health-related questions. It's always free to ask and you can upgrade for treatment if necessary.

Iora Health

Series B in 2013
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

EXOS

Venture Round in 2012
EXOS, Inc. is a human performance company based in Phoenix, Arizona, with additional facilities in Los Angeles, San Diego, Frisco, Miami, and Charlotte. Founded in 1999, EXOS specializes in training, nutrition, physical therapy, and consulting services tailored for professional athletes, as well as individuals and organizations in various sectors. The company offers a wide range of services, including facility design and management, performance assessments, rehabilitation, and wellness programs. With a focus on evidence-based strategies, EXOS has developed integrated solutions for workplace wellness, serving corporate campuses, military bases, health clubs, academic institutions, and sports organizations. Formerly known as Athletes' Performance, Inc., the company rebranded to EXOS in January 2014 and has established itself as a leader in performance training and physical therapy worldwide.

Adimab

Series F in 2012
Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

Pulmatrix

Series B in 2011
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, specializing in the development of inhaled therapies for serious pulmonary diseases. Utilizing its proprietary iSPERSE technology, Pulmatrix focuses on creating innovative dry powder delivery systems to enhance therapeutic delivery to the lungs. The company's product pipeline includes Pulmazole, an inhaled anti-fungal treatment for patients with allergic bronchopulmonary aspergillosis, and PUR1800, a narrow-spectrum kinase inhibitor aimed at treating obstructive lung diseases such as asthma and chronic obstructive pulmonary disease. Pulmatrix has established partnerships with RespiVert Ltd. for the development of kinase inhibitors and with Cipla Technologies LLC to commercialize Pulmazole. Founded in 2003, Pulmatrix aims to address significant unmet medical needs in respiratory health through its advanced therapeutic solutions.

Adimab

Series D in 2010
Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

Pulmatrix

Series B in 2009
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, specializing in the development of inhaled therapies for serious pulmonary diseases. Utilizing its proprietary iSPERSE technology, Pulmatrix focuses on creating innovative dry powder delivery systems to enhance therapeutic delivery to the lungs. The company's product pipeline includes Pulmazole, an inhaled anti-fungal treatment for patients with allergic bronchopulmonary aspergillosis, and PUR1800, a narrow-spectrum kinase inhibitor aimed at treating obstructive lung diseases such as asthma and chronic obstructive pulmonary disease. Pulmatrix has established partnerships with RespiVert Ltd. for the development of kinase inhibitors and with Cipla Technologies LLC to commercialize Pulmazole. Founded in 2003, Pulmatrix aims to address significant unmet medical needs in respiratory health through its advanced therapeutic solutions.

Pulmatrix

Series A in 2009
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, specializing in the development of inhaled therapies for serious pulmonary diseases. Utilizing its proprietary iSPERSE technology, Pulmatrix focuses on creating innovative dry powder delivery systems to enhance therapeutic delivery to the lungs. The company's product pipeline includes Pulmazole, an inhaled anti-fungal treatment for patients with allergic bronchopulmonary aspergillosis, and PUR1800, a narrow-spectrum kinase inhibitor aimed at treating obstructive lung diseases such as asthma and chronic obstructive pulmonary disease. Pulmatrix has established partnerships with RespiVert Ltd. for the development of kinase inhibitors and with Cipla Technologies LLC to commercialize Pulmazole. Founded in 2003, Pulmatrix aims to address significant unmet medical needs in respiratory health through its advanced therapeutic solutions.

Adimab

Series C in 2008
Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

Imprivata

Series C in 2008
Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.

Adimab

Series B in 2008
Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

EXOS

Series B in 2007
EXOS, Inc. is a human performance company based in Phoenix, Arizona, with additional facilities in Los Angeles, San Diego, Frisco, Miami, and Charlotte. Founded in 1999, EXOS specializes in training, nutrition, physical therapy, and consulting services tailored for professional athletes, as well as individuals and organizations in various sectors. The company offers a wide range of services, including facility design and management, performance assessments, rehabilitation, and wellness programs. With a focus on evidence-based strategies, EXOS has developed integrated solutions for workplace wellness, serving corporate campuses, military bases, health clubs, academic institutions, and sports organizations. Formerly known as Athletes' Performance, Inc., the company rebranded to EXOS in January 2014 and has established itself as a leader in performance training and physical therapy worldwide.

Adimab

Series A in 2007
Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

Adimab

Series A in 2007
Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

Ascend Health

Series B in 2007
Ascend Health Corporation is a behavioral healthcare provider that specializes in a comprehensive range of inpatient and day hospital services for individuals across various age groups, including children, adolescents, adults, and seniors. The organization operates freestanding psychiatric hospitals and offers a wide array of behavioral health programs, such as residential treatment centers, partial hospitalization, and intensive outpatient services. Ascend Health emphasizes personal choice and tailored care, ensuring that its services are effectively integrated with the local healthcare systems to deliver high-quality treatment for mental health and substance abuse issues.

EXOS

Series A in 2006
EXOS, Inc. is a human performance company based in Phoenix, Arizona, with additional facilities in Los Angeles, San Diego, Frisco, Miami, and Charlotte. Founded in 1999, EXOS specializes in training, nutrition, physical therapy, and consulting services tailored for professional athletes, as well as individuals and organizations in various sectors. The company offers a wide range of services, including facility design and management, performance assessments, rehabilitation, and wellness programs. With a focus on evidence-based strategies, EXOS has developed integrated solutions for workplace wellness, serving corporate campuses, military bases, health clubs, academic institutions, and sports organizations. Formerly known as Athletes' Performance, Inc., the company rebranded to EXOS in January 2014 and has established itself as a leader in performance training and physical therapy worldwide.

CodeRyte

Series C in 2006
CodeRyte is a leading provider of computer-assisted coding and clinical data extraction solutions tailored for the healthcare industry. The company offers advanced software that automates the coding process and efficiently analyzes physician narratives to uncover critical clinical information. Their product suite includes CodeAssist, a web-based tool that streamlines coding by integrating with operational information systems, CodeComplete, an outsourced coding solution, and DataScout, which extracts valuable clinical data from both free-text and structured medical records. CodeRyte's technology helps healthcare providers improve reimbursement accuracy, enhance compliance, and boost operational efficiency, making it a trusted partner for numerous physician practices, billing companies, and academic medical centers across the nation.

Imprivata

Series B in 2006
Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.

Asthmatx

Series C in 2005
Asthmatx, Inc. is a medical device company based in Mountain View, California, that specializes in the development and commercialization of therapeutic treatments for asthma. Founded in 2003, the company has created a technology that delivers controlled thermal energy to the airways of adult patients, aimed at reducing the mass of airway smooth muscle through a procedure known as Bronchial Thermoplasty. Asthmatx offers the Alair System, an interventional medical device designed for bronchoscopic treatment of patients suffering from moderate to severe asthma. As of October 2010, Asthmatx operates as a wholly-owned subsidiary of Boston Scientific.

Imprivata

Series A in 2005
Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.

Cardiac Dimensions

Series C in 2004
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

The Center from Health Promotion

Venture Round in 2003
The Center for Health Promotion Inc. delivers tobacco cessation and weight management services to customers nationwide. As an operating unit of Group Health Cooperative (Seattle) for almost 20 years, CHP developed the telephone-based Free & Clear program and established itself a national leader in tobacco cessation. Today CHP continues to deliver tobacco cessation services through health plans, businesses and labor organizations around the country. CHP also provides phone-based tobacco cessation services to residents of Georgia, Maine, Minnesota, Oklahoma, Oregon, Utah, Washington and Wisconsin through contracts with state agencies or coalitions. The company is actively engaged in research trials with major research centers including The Stanford Research Institute in Menlo Park, Calif., the Center for Health Research in Portland, Ore., and the Fred Hutchison Cancer Research Center and Group Health's Center for Health Studies, both in Seattle. This active research is undertaken to help improve CHP's services to smokers and increase scientific understanding of this key health issue.

Cardiac Dimensions

Series B in 2002
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

Sentillion

Series C in 2001
Sentillion, Inc. offers identity and access management technology solutions for caregivers in hospitals and healthcare organizations in North America and the United Kingdom. The company provides solutions for sign-on, user provisioning, clinical workstations, and virtualized remote access. The company offers expreSSO that delivers transparent single sign-on in existing workflows; Bridges, which provides a mechanism for interfacing to applications; and proVision that alters, disables, and terminates access to systems and applications. It also offers Vergence, which unifies single sign-on, single patient selection, and authentication services in clinical workstation solution that enables caregivers to access and navigate between the myriad of clinical and business applications. In addition, it offers vThere, which enables to manage clinicians and staff, such as medical transcriptionists, remote physicians, contractors, and temporarily displaced employees; and IdMPOWER that enables to accelerate the process of incorporating applications and information systems in the company's environment. The company offers implementation services, comprising project planning, installation, training, integrated testing, and deployment; and technical support services, including toll-free telephone support, trouble-shooting, and operational support. Sentillion, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.

Sentillion

Series B in 2000
Sentillion, Inc. offers identity and access management technology solutions for caregivers in hospitals and healthcare organizations in North America and the United Kingdom. The company provides solutions for sign-on, user provisioning, clinical workstations, and virtualized remote access. The company offers expreSSO that delivers transparent single sign-on in existing workflows; Bridges, which provides a mechanism for interfacing to applications; and proVision that alters, disables, and terminates access to systems and applications. It also offers Vergence, which unifies single sign-on, single patient selection, and authentication services in clinical workstation solution that enables caregivers to access and navigate between the myriad of clinical and business applications. In addition, it offers vThere, which enables to manage clinicians and staff, such as medical transcriptionists, remote physicians, contractors, and temporarily displaced employees; and IdMPOWER that enables to accelerate the process of incorporating applications and information systems in the company's environment. The company offers implementation services, comprising project planning, installation, training, integrated testing, and deployment; and technical support services, including toll-free telephone support, trouble-shooting, and operational support. Sentillion, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.

Accordant Health Services

Venture Round in 2000
Accordant provides its program members with healthcare advice. The service focuses on delivering support for patients with rare, chronic diseases. Its care management solutions comprise of tools and resources of professionals in the healthcare sector. The service also delivers care management services for rare diseases which include health plans, employers, and third party administrators. Accordant is a subsidiary of CVS Caremark. It was founded by Steve Schelhammer and is headquartered in Greensboro, North Carolina.

Sentillion

Series A in 1999
Sentillion, Inc. offers identity and access management technology solutions for caregivers in hospitals and healthcare organizations in North America and the United Kingdom. The company provides solutions for sign-on, user provisioning, clinical workstations, and virtualized remote access. The company offers expreSSO that delivers transparent single sign-on in existing workflows; Bridges, which provides a mechanism for interfacing to applications; and proVision that alters, disables, and terminates access to systems and applications. It also offers Vergence, which unifies single sign-on, single patient selection, and authentication services in clinical workstation solution that enables caregivers to access and navigate between the myriad of clinical and business applications. In addition, it offers vThere, which enables to manage clinicians and staff, such as medical transcriptionists, remote physicians, contractors, and temporarily displaced employees; and IdMPOWER that enables to accelerate the process of incorporating applications and information systems in the company's environment. The company offers implementation services, comprising project planning, installation, training, integrated testing, and deployment; and technical support services, including toll-free telephone support, trouble-shooting, and operational support. Sentillion, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.

Data Sciences International

Venture Round in 1997
Data Sciences International, Inc. is a biomedical research company specializing in systems physiology and pharmacology. Based in St. Paul, Minnesota, the company provides a range of telemetry devices, instrumentation, and software designed for physiological monitoring. Its product portfolio includes wireless solutions such as implantable telemetry transmitters and Bluetooth-enabled external devices that monitor various physiological parameters like ECG, blood pressure, and activity in freely moving animals. Additionally, DSI offers software platforms for data acquisition and analysis, as well as respiratory solutions, implantable glucose monitors, and infusion pumps tailored for laboratory animals. The company serves diverse sectors, including pharmaceuticals, academia, government, and biotechnology, and provides services such as validation, technical training, and surgical training related to its devices. Founded in 1984, DSI has established itself as a leader in physiologic monitoring, helping advance scientific research across multiple fields.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.